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VEditorial
he number of patients previously
submitted to percutaneous coronary
interventions with the implantation of stents
and subsequently referred for coronary
artery bypass graft surgery (CABG) has increased
considerably and is already a substantial part of the
surgical cases. However, corresponding concerns have
increased about the short-term and long-term results
of patients undergoing CABG after PCI with stent
implantation [1]. New scientific evidence seems to
reinforce this apprehension, with recent publications
highlighting findings of coronary endothelial
dysfunction over the long term, induced by new
generation of drug-eluting stents (DES).
Endothelial function, which is unequivocally
impaired by the insertion of bare metal stents (BMS)
[1], seems to be additionally injured by the use of DES.
Initially, Togni et al. [2] demonstrated that sirolimus
eluting stents (SES) (Cypher; Cordis, J&J) were
associated with exercise-induced paradoxic coronary
vasoconstriction, suggestive of endothelial
dysfunction induced by the drug as a subjacent
mechanism. Subsequently, Hofma et al. [3]
comparatively evaluated the coronary endothelial
function six months after BMS and DES implant. The
conclusion was that Cypher stent implantation
compromised the endothelial-dependent coronary
vasomotor response compared to BMS implantation,
even over the long term; the real clinical consequences
of these findings remain unknown.
The exacerbation of endothelial dysfunction
induced by DES may have several implications. Firstly,
low efficacy in the relief of the symptoms of angina as
endothelial dysfunction is involved in the mechanisms
triggering angina. Surprisingly, there are inconsistent
data in medical publications on the efficiency of the
use of DES in the relief of angina. The next consequence
of endothelial dysfunction is thrombosis. The rates of
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subacute and long-term thrombosis associated to the
use of BMS and DES were initially reported as being
similar. In the first studies, the accumulated incidence
of thrombosis with DES over 9 to 12 months varied
from 0.4% to 0.6% [1].
However, preliminary evidence of an increase of
subacute and long-term thrombosis with DES has been
found in metanalysis comparing the results of BMS
and DES [4]. Although clinical studies did not have
the statistical power to detect differences in the rates
of thrombosis, metanalysis suggests an increased risk.
Thus, the risk of acute myocardial infarction (AMI)
increased by 1.94 times with the use of DES (95% CI
from 0.89 to 4.23, p-value = 0.096). DES have also been
associated with a greater risk of thrombosis at a similar
degree to the risk observed for AMI [4].
Subsequent works showed that the incidence of
thrombosis with the use of DES in the real world was
at least double the first reported rate; close to 1.3%. In
a multivariate analysis, an early interruption of
antiplatelet use, renal insufficiency, coronary lesions
at bifurcations, diabetes and low ejection fraction were
identified as risk factors for thrombosis with the use
of DES. The mortality rate observed in patients with
DES thrombosis was 45% [5].
Recently, data from other studies showed that the
incidence of thrombosis with the use of DES is
increasing. In the ERACI III study [6] over a follow up
period of 18.3 ± 8.8 months (varying from 5 to 36
months), of 225 patients with DES implantation, 3.1%
presented with thrombosis. The time between stent
implantation and the occurrence of thrombosis varied
between 3 and 927 days. Thrombosis after stent
implantation was always associated to more significant
events such as death or AMI; late thrombosis was
identified after the cessation of antiplatelet medication.
This finding was reinforced by data reported in
the BASKET-LATE study [7]. This study compared
the long-term results (up to 18 months of follow-up) in
patients submitted to either BMS or DES implantation,
analyzing the incidence of clinical events related to
late thrombosis. The incidence of thrombosis was twice
as high in DES patients, with clinical events related to
thrombosis being two times more frequent in patients
treated with DES. The clinical events related to
thrombosis (defined as nonfatal AMI and death) were
3.3 times higher. Thrombosis with BMS tended to occur
in the first 150 days after cessation of clopidogrel,
while events related to DES occurred evenly
throughout the study period.
In the recent World Congress of Cardiology in
Barcelona, presentations of new metanalyses analyzing
the data published on the long-term use of the DES
brought important revelations.
The first metanalysis focused on double-blind
controlled randomized trials comparing DES and BMS.
In overall were studied 1685 patients submitted to
Cypher implantation versus 1675 cases with BMS from
the Ravel, Sirius, E-Sirius and C-Sirius studies; while
878 patients with Taxus versus 879 with CS were
included in the Taxus II, IV, V and VI studies. The
analysis concentrated in the main results of death (from
any cause), Q-wave AMI and combined death and Q-
wave AMI to reflect the incidence of stent thrombosis.
For studies of Cypher stents, the incidence of
combined death and AMI-Q was significantly greater
with drug-eluting Cypher stents than with BMS over
3 years (6% versus 4%) giving an relative risk increase
of 33%.
In the Taxus studies, the death rate plus AMI-Q
yielded a 1% higher relative risk with Taxus compared
with BMS over 3 years (3.5% versus 3.1%).
Subsequently, on analyzing the data over a longer
term, the incidence of death from any cause or AMI-
Q was 2.4% greater with the Cypher stent compared
to BMS (6.3% versus 3.9%) and 0.3 greater with Taxus
stents versus BMS (2.6% versus 2.3%). Additional
analysis of the data showed an increase of 38% in
the relative risk of events combined with death (for
all causes) and AMI-Q in patients with Cypher stents
compared to BMS and an increase of 16% in patients
implanted with Taxus stents versus the group with
CS [8].
Thus, the incidence of death together with AMI-Q
occurs is higher in patients with DES compared with
those with BMS, although the level of clinical events
observed with DES still needs to be clearly defined.
These findings reinforce the need of careful evaluation
of the risks and benefits with the indiscriminate use of
DES. Long-term thrombosis of the stent can
determinate AMI or death,both sudden or as a
consequence of secondary heat failure due to AMI.
Nordmann et al. [9], in another metanalysis,
presented important data about the total mortality rate
examining cardiac related and non-cardiac related
deaths separately. The odds ratio (OR) for death at 3
years was 1.25 for the combined data of both types of
DES, 1.25 for Cypher and 1.10 for Taxus when
compared with BMS.
Preliminary evidence suggests that Cypher, but
not Taxus, is associated to an increase in the incidence
of non-cardiac death. A long-term follow up and
reevaluation of specific causes of deaths in patients
who received Cypher stents is essential to determine
the safety of these devices. The commonest causes
of deaths in patients who received Cypher stents
were cancer (mainly lymphomas), sepsis, pneumonia
and other infections, strokes and pulmonary
embolism. The suggested explanation would be a
rapid deterioration of the immune system after stent
implantation with the drugs and the prothrombotic
systemic effects.
Clearly, satisfactory results after DES implantation
are strongly dependent on the long-term use of
antiplatelet drugs. However 25% of the patients taking
clopidogrel are resistant to the drug, without an
adequate platelet antiaggregation response. These
patients are at continual risk of increased thrombotic
complications after PCI [10].
Other consequences of endothelial dysfunction
are graft failure, the progression of coronary
atherosclerotic disease and heart failure. These critical
aspects remain little studied and are still relatively
unknown. From the early concerns [1, 11], a growing
amount of evidence suggests that patients who were
previously submitted to PCI/stent may not fully benefit
of further CABG.
Kamiya et al. [12] compared the immediate and late
patency of grafts in patients with and without previous
PCI. Graft patency of the left internal thoracic artery
anastomosed to the left anterior descending artery in
patients who had previously undergone PCI tended
to be lower than in patients who had not been
submitted to this procedure. Gaudino et al. [13]
performed a prospective randomized study to evaluate
graft patency in patients with stent restenosis who
were subsequently submitted to CABG. After 5 years
of follow-up, the venous grafts had a higher incidence
of occlusion among patients who had previously been
submitted to coronary stent implantation.
Subsequently, Hassan et al. [14] assessed the
impact of prior PCI on the in-hospital death of patients
submitted to CABG. Using multivariate analysis, prior
PCI emerged as an independent predictor for
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postoperative hospital mortality (p=0.003). Comparing
the two groups of patients, the in-hospital mortality
rate was higher among patients previously submitted
to PCI (3.6% versus l.7%; p=0.01). The long-term
results remain unknown, as does the impact of this
factor on the benefits of the surgery.
Thielmann et al. [15] studied the relationship
between the perioperative risks during elective
coronary artery bypass graft surgery in patients with
prior multiple PCI. The multivariate analysis by logistic
regression revealed that multiple PCI were strongly
associated with hospital mortality (p< 0.001).
Fragomeni et al. [16] studied left ventricular
function (LVEF) in patients initially submitted to PCI/
stent and afterwards submitted to CABG, with a mean
time interval of 9.5 months between the two
procedures. Comparing the pre-PCI ventricular
function with the LVEF obtained just before surgery,
demonstrated that 39.2% of patients had significant
reductions. The drop in the LVEF is associated to a
worse long-term prognosis.
The morphological, structural and physiological
alterations of the myocardium and coronary artery
induced by the inflammatory reaction consequent to
DES implantation have been little studied and are not
well understood [1]. DES implantation causes intense
structural alterations in the wall of coronary arteries,
both at the site of implantation and in the surrounding
region. The wall of the coronary artery close to the
stent is almost completely replaced by collagen
(fibrosis) with intense leukocyte infiltration [11,17].
This histological alteration of the coronary artery
structure is in consonance and helps to explain the
long-term endothelial dysfunction. Both the
inflammatory reaction and the induced endothelial
dysfunction are probably irreversible, at least for some
patients.
Joner et al. [18] studied the effects of DES on
the repair mechanisms of the coronary artery in
autopsies and the correlation of these with late stent
thrombosis (LST). LST was observed in 61% of cases
with DES implants. After 60 days of Cypher stent
implantation, the the coronary artery wall showed
inflammatory reaction with infiltration of eosinophils
and giant cells,  while with the Taxus stent
implantation, deposits of fibrin and less
inflammatory cells infiltrate predominated. After 120
days, patients implanted with Cypher stents showed
focal deposits of fibrin and a reaction of giant cells,
while Taxus implants demonstrated greater
inflammatory reactions, consisting in the infiltration
of lymphocytes, eosinophils and macrophages.
Deficient healing of coronary artery lesions with
incomplete endothelization was found in all cases
with LST. Incomplete endothelization is one of the
pathological substrates involved in the emergence
of LST.
Thus, there is evidence of irreversible involvement
of the structure and endothelial function of the
coronary artery wall. Based on this evidence, the
procedure of stent implantation is characterized as the
most paradoxical method for treatment of coronary
artery disease (CAD). That is, to treat a condition
(coronary artery disease) that is first and foremost an
inflammatory disease (and progressed due to the
associated endothelial dysfunction), the result is an
aggravation of the inflammatory disease and
worsening of the endothelial function. Currently, CAD
is no longer characterized as merely a hydraulic
problem but as a metabolic disease, where the
inflammatory process and endothelial dysfunction
have prime importance in its genesis and progression.
However, the complications originating from
coronary stent implantation (stent failure) is
characterized as a new clinical entity. Will the
medications and surgical procedures now used have
the same effectiveness in the treatment of this new
disease? Due to the progression of the induced
endothelial dysfunction, can relief of the angina (both
using medicines and surgery) be as effective in this
patient?
As CAD is a progressive disease and the number
of patients submitted to stent/PCI and subsequently
referred to coronary artery bypass graft surgery is
increasing, there is a necessity to reassure that these
events will not put long-term results provided by
coronary artery bypass graft surgery at risk.
Additionally, the best operative method and the impact
of the intensive use of arterial grafts are still to be
identified, as is the effect of the intensive use of statins
and angiotensin converting enzyme inhibitors.
Moreover, as new types of stents, specifically
DES and absorbable stents (so-called second
generation DES), are ready to arrive on the market,
specific complications related to each one of them
should be expected. The identification of these
complications can contribute to a reduction in
associated adverse events with a consequent
improvement in clinical results.
Thus, the morphological and physiological
alterations caused by the use of stents in coronary
arteries and the clinical repercussions have been little
studied. It is evident that CABG cannot offer the ideal
results to patients with immediate and long-term
complications caused by PCI and coronary stent
implantation. Moreover, there is a necessity to
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accurately monitor, by an independent organization,
the adverse effects and events resulting from the use
of DES.
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